Rukobia 600 mg prolonged-release tablets
205888
Phase 3 small_molecule active
Quick answer
Rukobia 600 mg prolonged-release tablets for Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1 is a Phase 3 program (small_molecule) at ViiV Healthcare BV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ViiV Healthcare BV
- Indication
- Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active